Merck & Company Inc (MRK)vsPrivia Health Group Inc (PRVA)
MRK
Merck & Company Inc
$110.95
-1.60%
HEALTHCARE · Cap: $274.03B
PRVA
Privia Health Group Inc
$24.69
-0.60%
HEALTHCARE · Cap: $3.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2962% more annual revenue ($65.01B vs $2.12B). MRK leads profitability with a 28.1% profit margin vs 1.1%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PRVA
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Margin of Safety
+70.2%
Fair Value
$72.49
Current Price
$24.69
$47.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Earnings expanding 132.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
17.4% revenue growth
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
ROE of 4.0% — below average capital efficiency
1.1% margin — thin
Operating margin of 2.1%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PRVA
The strongest argument for PRVA centers on EPS Growth, Debt/Equity, Altman Z-Score. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PRVA
The primary concerns for PRVA are Return on Equity, Profit Margin, Operating Margin. A P/E of 137.2x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
MRK profiles as a value stock while PRVA is a growth play — different risk/reward profiles.
PRVA carries more volatility with a beta of 0.87 — expect wider price swings.
PRVA is growing revenue faster at 17.4% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 48/100), backed by strong 28.1% margins. PRVA offers better value entry with a 70.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Privia Health Group Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?